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Intensive efforts in recent years to develop and commercialize in vitro alternatives in the field of risk
assessment have yielded newpromising two- and three dimensional (3D) cell culturemodels. Nevertheless, a
realistic 3D in vitro alveolar model is not available yet. Here we report on the biofabrication of the human
air-blood tissue barrier analogue composed of an endothelial cell, basement membrane and epithelial cell
layer by using a bioprinting technology. In contrary to the manual method, we demonstrate that this
technique enables automatized and reproducible creation of thinner and more homogeneous cell layers,
which is required for an optimal air-blood tissue barrier. This bioprinting platform will offer an excellent
tool to engineer an advanced 3D lung model for high-throughput screening for safety assessment and drug
efficacy testing.
I
n the field of regulatory toxicity animal testing is still the most prevalent model used for risk assessment, study
of diseases and new drug development1. However, three main factors create a strong need for in vitro alter-
natives2,3: Regulatory pressure to ban animal testing4, pressure to reduce cost in drug development5, and
concerns with respect to the significance of animal experiments tomodel human health6. Therefore, new concepts
for more efficient, cheaper and evidence-based test strategies were proposed such as cell culture models which
provide the possibility to investigate processes such as toxic effects on human cells, which cannot be conducted in
vivo where mainly rodents are used. Besides having the potential to replace traditional animal experiments, in
vitro models represent a sophisticated and reproducible system that allows us to deconstruct and manipulate
complex cellular pathways7, hence they can be used as a first step towards understanding how an agent will react
in the body. The lung is the main portal of entry for aerosols (reviewed in8) and despite the existence of epithelial
tissue barriers, respiratory diseases are frequent and increasing9,10. Recently, more attention has been directed
towards elucidating how and when the antigens evade these barriers and therefore many alternative cell models
have been established11.
Respiratory tissue engineering has advanced significantly within the last years and several approaches are
described in the literature that can be used tomimic the human pulmonary epithelial tissue barrier by applying 2D
and 3D models ranging from simple mono-cultures12,13 to highly sophisticated 3D constructs including co-
cultures of various cells and/or scaffold supports14–17. 3D cell cultures represent advanced, more complex systems
since they involve cell-cell interactionsmimicking the native tissue and its microenvironmentmore realistically17.
In the last decade, in vitro cell culture models that closely mimic the conducting airways as the trachea and
bronchi’s, were introduced on themarket (e.g. products of Epithelix Sa`rL, CellnTec GmbH). Nevertheless, a huge
gap remains in recreating in vitro alternatives that realisticallymimic the human air-blood tissue barrier structure.
In addition, a great drawback of the current co-culture models is the use of commercially available two chamber
systems, as well as culturing different cell types on two sides of a relatively thick (about 10 mm) porousmembrane
composed of materials such as for example poly-ethylene terephthalate (PET). This is not optimal for the
development of an air-blood barrier model where the real barrier corresponds merely to two very thin cytoplas-
mic lamellae of the endothelial and epithelial cells separated by a single basement membrane (BM); the average
overall thickness of this tissue barrier amounts to about 1.6 mm18,19.
Significant progress in microfluidic technology has demonstrated a great potential for developing advanced
cellular and tissue structures with high physiological relevance, such as the biomimetic microdevices also called
‘‘organs-on-a-chip’’, which will be extremely useful systems for testing new drug candidates or risk assessment of
engineered nanomaterials20–23. The introduction of cyclical mechanical strain simulating breathing conditions in
the lung also enabled a huge step forward in recreating realistic models of the respiratory tissue20,21,24. The lung on
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a chip platform described byHuh et al.20 combined alveolar epithelial
and microvascular endothelial cells in two closely apposed micro-
channels separated by a 10 mm porous, flexible membrane to mimic
the architecture of the air-capillary barrier. The cyclic stretching of
the interface simulating breathing motions was introduced by
vacuum chambers on the side. This microsystem was later used to
model drug toxicity induced pulmonary edema21. Recently, another
system, i.e. the captive bubble surfactometer, was introduced allow-
ing to investigate lung cell structure and function in vitro under
breathing conditions24.
A different approach in tissue engineering strategies has enabled the
emergence of bioprinting technology employing cells and bioactive
matrix components25,26 for design and biofabrication of in vitro
physiological models that is expected to tremendously impact our
understanding of physiological mechanisms, disease pathologies and
significantly enhance drug development. The great power of bioprint-
ing technology is to (i) provide standardized and reproducible cell
models for high-throughput screening, (ii) customization of specific
(diseased) tissue models, and (iii) the possibility to spatially and tem-
porally control the deposition of biomaterials to generate complex 3D
constructs in a layer-by-layer fashion27,28. Along with the development
of various bioprinting strategies (reviewed in27,29–32) there has been
increasing interest in implementing these for applications in regen-
erative medicine, cancer research, but also for use in drug discovery,
toxicology or basic research30. Until now 3D bioprinting methods have
been used to create multiple tissue types, including cardiac33–36, bone
and cartilage tissue36–40, vascular networks41–43, multi-layered skin44
and nerve grafts45,46. Cell printing platforms were applied to construct
3D tumor models47,48 to mimic/simulate the physiological tumor
microenvironment. Other studies reported about the development
of bioprinting processes to create liver micro-organ for examining
in vitro drug metabolism and pharmokinetics49,50 and to deposit
human embryonic stem cells directly on microwell plates, resulting
formation of spheroid aggregates51. These promising examples
employing cell bioprinting could pave the way for establishing more
accurate models for in vitro drug development and toxicity testing.
To best of our knowledge no work so far has been reported about
lung tissue engineering using 3D bioprinting. The scope of our work
was to develop a complex, yet reproducible and fully automatized,
engineered 3D air-blood tissue barrier using an innovative valve-based
bioprinting approach. An existing bioprinter, the BioFactoryH
(Fig. 1a–b; regenHU Ltd., Switzerland), has been adapted to engineer
Figure 1 | Bioprinting system, fabrication of 3D constructs and schematic illustration of the cell patterning timeline process. (a) The BioFactoryH is a
bioprinter developed for creating 3D organotypic structures for tissue engineering and drug discovery. The main component of the instrument is (b) the
process unit comprising the tool changer (1) with 3 workstations equipped with print heads and the building cell area with the building platform (2).
(c) Schematic of the timeline for bioprinting the two cell-layer barrier system. On day 0, a thin layer of extracellular matrix (ECM) is printed on porous
membranes, and subsequently a layer of EA.hy926 endothelial cells is printed onMatrigelTM. On day 2, a second ECM layer is printed on endothelial cells
to ensure the adhesion of the next printed layer of A549 epithelial cells. The cells are cultivated for additional 3 days before their 3D organization, viability,
proliferation and barrier quality are assessed. The manual co-culture assembly follows the timeline described for bioprinting including the same steps
however made manually, i.e. manually pipetting the ECM/cell layers.
www.nature.com/scientificreports
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a human air-blood barrier analogue consisting of A549 (alveolar epi-
thelial type II cells; AT-II), EA.hy926 (endothelial) cells separated by
thin BM MatrigelTM by applying a layer-by-layer printing approach
(Fig. 1c) in order to optimize cell culture conditions in regards to the
structure and function of the human organ. Initial experiments have
been performed using epithelial and endothelial mono-cultures, which
were then further assembled into co-cultures and the functional-struc-
tural relation of the tissue constructs was examined by various state-
of-the art methods. In addition, we report on the comparison between
two approaches for 3D tissue modelling, i.e. conventional manual
versus bioprinting.
Results
Comparison of cellular morphology and cell-cell contacts in
manually seeded and bioprinted cultures. To study the 3D
structure of cells printed on MatrigelTM in single and co-cultures and
to compare it with the conventional manual method, cells were fixed
after three days in culture and investigated with laser scanning
microscopy (LSM). According to the confocal micrographs obtained
following immunostaining of the cells for F-actin (green) and nuclei
(white) it could be shown that both, endothelial (Fig. 2a–b) and
epithelial cells (Fig. 2c–d) exhibited different morphology depending
on the seeding method, i.e., manual (Fig. 2a, c) vs. printing (Fig. 2b, d).
Cells seeded by conventional manual method typically grew in patches
(Fig. 2a, c) often overgrowing each other formingmulti-layered clusters
(side views of Fig. 2a, c), although the cells were also seeded as single
cells and not in clumps as shown by phase contrast pictures
(Supplementary Fig. S1). In contrast, the corresponding printed cells
(Fig. 2b, d) spread over the available growth surface to form confluent
thin monolayers (side views of Fig. 2b, d). A549 cells had typical
polarized, cuboidal morphology52, while EA.hy926 cells formed
simple flat sheets covering larger growth surfaces. The bioprinting
process was fine-tuned in order to achieve very thin layers of
MatrigelTM that induced a more optimal growth of the epithelial and
endothelial cells, i.e. they formed thin cell layers as mentioned above.
Similar results were observed for the two cell-layers of EA.hy926
and A549 cells (Fig. 3). For these experiments we have used A549
cells labelled with green fluorescent protein (GFP) to distinguish
them from the endothelial cells. The GFP-A549 cells grew similar
to non-labelled cells (data not shown). Themanual seeding approach
often produced in addition to discrete multi-layered clusters an
apparent thick ECM layer between endothelial and epithelial cells
(Fig. 3a, yellow arrowheads pointing to dark regions designating the
basement membrane and Fig. 3a close-up) resulting often in a lack of
direct cell-cell contacts/communication of different cell types. On the
other hand, printed cell layers are structurally in close proximity to
each other (Fig. 3b close-up), ensuring complex cell-cell interactions,
hence having higher structural and functional resemblance of com-
plex cell networks found at the air-blood barrier in vivo. Due to the
fact that the BM layers were not visible by LSM, we investigated the
two cell-layers by brightfield microscopy following Masson Goldner
trichrome staining of paraffin embedded histological sections
(Fig. 3c, d). This staining method is recommended for distinguishing
cells from surrounding connective tissue, specifically collagen.
Representative brightfield micrographs of stained manual (Fig. 3c)
and printed co-cultures (Fig. 3d) corroborate our previous observa-
tions with LSM, i.e. presence of thick BM layers by manual approach
(Fig. 3c green staining) and thin printed layers that are hard to detect
in the samples even with the employed histological staining.
Figure 2 | Characterization and comparison of manually seeded and
bioprinted mono-cultures by LSM. Immunofluorescence labelling of F-
actin cytoskeleton ( ) and nuclei ( ) in (a,b) EA.hy926 and (c,d) A549
mono-cultures cultivated for 3 days following (a,c) manual seeding and
(b,d) bio-printing on MatrigelTM BM. Endothelial cells were labelled in
addition with specific cell adhesionmarker PECAM-1 (platelet endothelial
adhesionmolecule also referred to as CD31 ( )). Single optical sections are
presented in the x-y projection (central image) with respective side views in
xz (bottom). Scale bars correspond to 20 mm.
Figure 3 | Characterization and comparison of manually seeded and
bioprinted co-cultures by LSMand brightfieldmicroscopy. Laser scanning
micrographs of two cell-layers composed of first layer of MatrigelTM BM,
endothelial cells, second MatrigelTM layer, and epithelial cells by (a) manual
and (b) bioprinting approaches after 3 days. All cells were stained for F-actin
(red) and nuclei (white). A549 cells are represented in green, endothelial cells
were labelled with VE-cadherin (pink). Note the formation of cell multilayers
and the presence of thick MatrigelTM layer (yellow arrowheads) under
manual condition. Images are presented in xy projections with representative
side views. Parts of side views are magnified for better visualization of cell-cell
contacts. Brightfield micrographs of (c) conventionally seeded and (d)
bioprinted paraffin embedded histological cross sections stained with
Masson-Goldner trichrome coloration. Cytoplasm is stained red, collagen
fibers of the ECM MatrigelTM green and cell nuclei dark brown. Note the
thick ECM layers in c) which are hardly visible in d). Scale bars are (a–b)
50 mm, (a-b close-up) 10 mm and (c–d) 100 mm.
www.nature.com/scientificreports
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Assessment of cell growth, viability and integrity of manually
seeded and bioprinted cultures. A phase-contrast microscope
integrated in a tissue culture incubator (Nikon Biostation CT;
Nikon Instruments, Zurich, Switzerland) was used to observe the
growth of endothelial-, epithelial mono-cultures and the co-
cultures over a 3 day experimental period (Fig. 4a–f). Compared to
the conventional manual seeding where cells grow typically in
discrete spheroid-like clusters, which can be observed already 2 h
after seeding (Supplementary Fig. S1, Fig. 4a, c and Supplementary
Movies S1, S3), both, printed EA.hy926 (Supplementary Fig. S1,
Fig. 4b and Supplementary Movie S2) and A549 cells
(Supplementary Fig. S1, Fig. 4d and Supplementary Movie S4)
show homogeneous distribution and exponential growth over the
surface of membranes and reach confluence on the 3rd day of
incubation. Figures 4e and 4f display merged phase contrast and
fluorescence micrographs of co-cultures assembled by manual
(Fig. 4e) and printing (Fig. 4f) approach (see also Supplementary
Movies S5 and S6). Endothelial (phase contrast) and epithelial cells
(designated green fluorescent on same micrographs) exhibited
similar growth to the respective mono-culture conditions, i.e.,
heterogeneous discrete clusters under manually seeded conditions
and homogeneous cell distribution when the bioprinting approach
was employed. At the last time point (Fig. 4e, f: 72 h), cells reached
near-confluence state in both conditions (A549 cells are visible only).
The cell viability was assessed by Trypan Blue exclusion assay after
24 h and by measuring the activity of lactate dehydrogenase (LDH)
released into the cell culture medium of samples after 3 days yielded
by the conventional manual and the novel bioprinting approach.
Manually seeded cells being in culture for 24 h displayed high viab-
ility with dead cells occurring only occasionally (Supplementary Fig.
S2). Printed epithelial cells showed higher viability than printed
endothelial cells as displayed on representative micrographs of
Supplementary Figure 2. Cells incubated in 70% ethanol for
30 min served as positive controls resulting in 100% blue labelled
cells. For LDH release measurements, cells lysed with Triton X-100
(treated for 24 h prior to the endpoint) revealing themaximum LDH
release were considered as the reference point (positive control; value
5 100%) that is indicated as dashed red line on the plot (Fig. 4g). The
viability of the endothelial and epithelial mono-cultures or co-cul-
tures was essentially similar regardless of the approach (manual vs.
printing) used. The percentage of dead A549 cells and epithelial-
endothelial co-cultures was similar and below 5%, whether the cells
were seeded by manual or printing method yielding an overall viab-
ility of . 95% for these cultures. Endothelial cells were found to be
more sensitive with 14.2% 6 4.5% dead cells after bioprinting and
10.4%6 5.4% dead cells followingmanual seeding resulting in about
$ 86% cell survival on the 3rd day of cultivation.
The barrier quality (i.e. tightness) of A549 and EA.hy926 cells in
mono- and co-culture was investigated by measuring the transloca-
tion of Blue Dextran molecules from the apical to the basolateral
compartment of the inserts after 3 days of cell growth. The overall
leakage of Blue Dextran in an empty transwell insert without cells
was used as the reference point (negative control; value 5 1) and is
indicated as dashed red line on the respective plot (Fig. 4h). Printed
mono-cultures of the two cell types showed higher tightness than the
corresponding manual samples with epithelial cells showing signifi-
cantly higher barrier qualities as compared to endothelial cells (both
manual and printed). Printed endothelial cells were significantly less
permeable than manually seeded cells while no significant difference
was found between printed vs. manual epithelial cells. On the other
hand, themanually assembled co-culture of EA.hy926 andA549 cells
allowed significantly lower translocation of Blue Dextran than in the
case of printed sample. This phenomenon, i.e. seemingly tighter
barrier in manual co-cultures can be explained by the presence of
manually dispersed thick layers of ECM in contrast to thin ECM
layers achieved by printing. Namely, we have observed that ECM
thickness influences the translocation of Blue Dextran under acellu-
lar conditions (Supplementary Fig. S3) insinuating that manual and
printed co-cultures have similar barrier qualities.
Discussion
In this study we demonstrate for the first time, the engineering of a
lung tissue analogue closely recapitulating the in vivo human air-
blood barrier architecture with a highly precise, reproducible bioma-
nufacturing technique. The applied prototyping technology was a
valve-based bioprinting process for layer-by-layer fabrication of
3D tissue constructs. Initial experimentation for testing the posi-
tional repeatability and accuracy of the printer showed that this
technology enables highly precise and reproducible patterning in a
controlled spatial arrangement (Supplementary Fig. S4). The print-
ing process was optimized to operate under cell friendly low pressure
conditions to deposit multiple cell types and ECM.
The two cell-layer model was designed in order to achieve a close
physiological resemblance to the microenvironment of the native
tissue, where the epithelial cell layer is only separated by a thin BM
from the underlying endothelium. Similarly, we employed
MatrigelTM BM extract that corresponds to authentic BM53,54. In
our system, cells and ECM were assembled in 3D on a microporous
membrane that served merely as a support for the printing process
unlike previously developed 3D in vitromodels of the alveolar barrier
where the membrane was used to mimic the basement mem-
brane14,15,52, with different cell types cultured on both sides of a
microporous membrane, which is foreign (non-biomimetic) and
considerably thick restricting direct cell-cell interactions and thus
limiting their biological relevance. In the here presented in vitro
model we employed cell lines that have the inherent advantage of
being homogeneous and more stable in comparison to primary
human epithelial and endothelial lung cells16 and, hence, ensuring
better control and reproducibility when performing screening tests.
Such an approach will also allow an interlaboratory comparison.
Nevertheless, in a further step we will evaluate the possibility to print
primary cells, to reflect even a more realistic in vivo situation.
The integration of a dynamic system simulating breathing
motions into models reconstituting the air-blood barrier has been
proven by previous research20–22,24 to be crucial for recapitulating the
in vivo situation at the air-liquid interface adding them an unpre-
cedented value in terms of tissue functionality. We therefore aim to
explore in the future the possibilities of combining cell printing with
mechanically active microfluidic systems. Chang and co-authors
have previously shown that a combinatorial setup of a 3D cell print-
ing process and a microfluidic environment enabled the creation of
an improved higher fidelity in vitro micro-liver tissue analogue,
which might be useful in drug and toxicology screening50.
Morphological analysis revealed considerable differences between
the two seeding approaches, both with respect to mono and co-cul-
tures: conventional manual seeding resulted in the formation of
multi-layered often discrete cell clusters which were embedded in
thick MatrigelTM layers (Fig. 3) with a thickness of about 20–30 mm
that may have significant impact on direct cell-cell interactions. In
comparison, by optimizing the printing process, very thin layers of
MatrigelTM (about 1–2 mm) could be obtained inducing a more
optimal growth of the epithelial and endothelial cells, i.e. are struc-
turally in a very close interaction, exhibiting a thin, outstretched
morphology similar to physiological conditions that promote cell
functionality. In the former case, the dispersion of a very thin
ECM layer is limited by the fact that this hydrogel starts to form a
gel at above 10uC, a process which cannot be avoided by manual
pipetting. On the other hand, the bioprinter dispensing system is
equipped with a temperature controlled unit that ensures a constant
temperature for thermo-sensitive biomaterials during the printing
procedure.
www.nature.com/scientificreports
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Figure 4 | Qualitative analysis of cell proliferation and evaluation of cell viability and tightness of mono- and co-cultures assembled by two different
approaches. Representative photomicrographs of manually seeded (a) EA.hy926, (c) A549 mono-cultures, (e) EA.hy926-A549 co-culture and
printed cells: (b) EA.hy926, (d) A549 and (f) co-culture over 72 h in culture (Figs a-d are phase-contrast micrographs; Figs e-f aremerged images of phase
contrast and fluorescence micrographs). Scale bars correspond to 200 mm. (g) Cell integrity was estimated by quantification of extracellular LDH release
(percent increase) relative to the positive control (Triton X-100 for 24 h; red dashed line) 3 days after printing ( ) or manual seeding ( ) of cells on
MatrigelTM. (h) Translocation of Blue Dextran was assessed on the 3rd day of mono- and co-culture assembly on printed ( ) and manually seeded ( )
cultures. The values are shown as fold increase related to the negative control (insert only, w/o cells). All results are expressed as the mean 6 standard
deviation of n53 independent experiments (*p , 0.05).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 7974 | DOI: 10.1038/srep07974 5
We further detected high cell viability (. 95% for epithelial cells
and co-cultures and$ 86% for endothelial cells) and proliferation of
the investigated cell types, both in mono- and co-cultures, which was
essentially similar regardless of the employed approach (manual or
printing). In this regard, we demonstrate that the valve-based print-
ing which is considered to be the gentlest among the existing tech-
niques for cell printing51, did not affect the majority of cells as
evidenced by LDH-release measurements and by qualitative analysis
of cell proliferation (Fig. 4a–g and Supplemetary Fig. S2). Moreover,
printed epithelial and endothelial mono-cultures exhibited tighter
layers than the corresponding manual cultures due to the fact that
manually seeded cells organize in clusters resulting in patchy non-
uniform cell layers, while printed cells have more uniform out-
stretched morphology (Fig. 2, 3). The observed higher permeability
of endothelial cells (Fig. 4h) can also be explained with their bio-
logical function, i.e. the relatively leaky occluding junctions between
the cells in vivo allow for nearly unlimited exchange of water, solutes
and smaller macromolecules between the blood plasma and the
interstitial space55. Similar observation, i.e. high permeability of
EA.hy926 cells has already been reported by Klein et al.15. The tight-
ness of co-cultures produced by using two approaches was similar
taking into account the barrier function of thick ECM layers that
were present in manually established co-cultures.
The lack of a highly reliable and commercially available 3D in vitro
alveolar model represents a major bottleneck for the development of
efficacious and safemedicines acrossmany therapeutic areas and risk
assessment for inhaled xenobiotics or nanoparticles, such as envir-
onmental particulates or combustion-derived particles. In this pro-
ject we communicate results on generating 3D alveolar tissue with a
bioprinting approach, which is the first step towards the validation of
printed lung tissue. In the near future, this novel approach will allow
us to provide a realistic, automatized and easy to handle in vitro
model for hazard assessment in the field of regulatory toxicology
as well as for the development of new inhalative medicine.
Methods
Bioprinting platform and control software. The BioFactoryH (regenHU Ltd.,
Switzerland) is a three-dimensional (3D) bioprinter with a printing resolution in the
micrometre range (, 5 mm) and smallest printable volumes in the range of 5–10 nL.
The platform consists of a desktop instrument enclosed within a sterile hood and a
human machine interface (HMI) control software. The main component of the
instrument is the process unit comprising (i) the tool changer with three workstations
(upgradable to six workstations) equippedwith print heads that allows for printing up
to 3 different biomaterials/cells and (ii) the building cell with amicrometre-resolution
three-axis building platform for biofabrication of 3D objects. The dispensing system
consists of a CF300N valve-based print head, which can be used for jetting or contact
dispensing with additionally mounted needle tip. The workstation used for ECM
patterning was equipped with a temperature control unit that ensures a constant
temperature along the whole dispensing system. ECM was printed by contact
dispensing, while cells were printed with jetting. The material flow is controlled by an
exchangeable micro valve that is mounted in the print head support housing the
solenoid that generates the power to open the valve. The ECM/cells suspension is
filled in cartridges, which are interconnected with print heads through a Luer-Lock
thread adapter and an inlet adapter. The dispensing unit requires air pressure for the
biomaterials to be dispensed from cartridges, which is supplied from a central inlet
equipped with an air filter. The air is spread through air spouts to each station where
the desired pressures are adjusted by individual pressure regulators. The hardware is
controlled via the HMI control software. For designing patterns/scaffolds we used
BioCAD (version 1.0), a 3D drawing suite developed by regenHU Ltd. From the
pattern information defined in BioCAD a g-code file was created, loaded to HMI and
launched after adjusting the printing parameters summarized in Supplementary
Table S1.
Array printing.An experiment was carried out to test the positional repeatability and
accuracy of the BioFactoryH, i.e., whether the precision of the manipulator is high
enough to return to previous positions defined by specific coordinates without
drifting in x or y direction. The models created for the control of the accuracy were a
multi-layered circular grid scaffold and the logo of Adolphe Merkle Institute
representing a more complex pattern, both printed from Nivea cream
(Supplementary Fig. S4a–b). The former model was a circular (10 mm in diameter)
scaffold with a height of 3 mm filled with coloured cream in the pores. It was made of
alternating layers with vertical and horizontal lines with a porosity of about 60%.
Between each layer, the space between the lines was filled with droplets of Nivea
cream coloured with red food dye (both can be found at Migros AG) to show that
multiple print head can be used on the same construct with a high repeatability and
space accuracy.
Cell culture. Experiments were carried out with the human alveolar epithelial type II
cell line A54956, and the EA.hy926 hybrid human cell line derived by fusing human
umbilical vein endothelial cells (HUV-EC) with A549 cells57. Both cell lines were
obtained from the American Type Culture Collection (ATCC, USA). For co-culture
experiments A549 cells stably expressing the eGFP protein were used, which were
kindly provided byDr. B. Schwaller, Department ofMedicine, University of Fribourg.
The cells were cultured in the following media: A549 cells were maintained in RPMI
1640 (Gibco, Life Technologies Europe B.V., Zug, Switzerland); EA.hy926 cells were
cultured in DMEM medium (Gibco) and the co-culture of the two cell types was
cultivated in 151 RPMI 1640: DMEM medium. The cell culture media were
supplemented with 10% (v/v) fetal bovine serum (FBS; PAA Laboratories, Chemie
Brunschwig AG, Basel, Switzerland), 1% (v/v) L-Glutamine (Life Technologies
Europe) and 1% (v/v) penicillin/streptomycin (Gibco). The cells weremaintained in a
humidified incubator (37uC, 5% CO2), medium was changed every 2–3 days and the
cells were subcultured through trypsinization when reached near-confluence. Initial
cell concentrations were calculated using Trypan blue exclusion method (0.4%
Trypan blue solution, T8154; Sigma Aldrich Chemie GmbH, Buchs, Switzerland).
The working cell concentrations were prepared by diluting cells with cell culture
medium. For the experiments, cell suspensions were prepared at a density of
4.5 3 106 cells/mL.
Extracellular matrix substrate and cell preparation for bioprinting. BDMatrigelTM
BM Matrix Growth Factor-Reduced (BD, 356230; concentration: 7.8 mg/mL;
subsequently referred to as ‘‘MatrigelTM’’) was thawed overnight at 4uC on ice and was
kept cool on ice until further use. For the printing procedure, MatrigelTM was loaded
in a sterile 3cc cartridge that was previously connected with a Luer-Lock adapter to a
print head. The cartridge containing the ECM was constantly cooled with a
minichiller (Huber Swiss Services GmbH, Mo¨hlin, Switzerland) that maintained a
constant cartridge temperature at 5uC. A predefined circular pattern filled with
horizontal lines designed in BioCAD software was loaded to the HMI interface of the
printer and a thin layer ofMatrigelTM was printed with contact dispensing microvalve
CF300 (MVC03-006; regenHU Ltd.; nozzle diameter 0.3 mm) on MillicellH-CM
Organotypic tissue culture plate inserts (PICM ORG 50; BioporeTM CM
hydrophilized PTFE membranes with a growth area of 4.2 cm2 and 0.4 mm pores in
diameter; Milllipore AG Zug, Switzerland) with printing parameters summarized in
Supplementary Table S1. The cell culture inserts with a printed layer of ECM were
incubated at 37uC for 30 min. Next, EA.hy926 or A549 cells suspended in cell culture
medium (former in supplemented DMEM, latter in supplemented RPMI 1640) at a
density of 4.5 3 106 cells/mL were loaded in sterile 3cc cartridges and one layer of a
repeated circular BioCAD pattern was printed with jetting microvalve CF300
(MVJ01-006; regenHU Ltd.; nozzle diameter 0.1 mm) and parameters found in
Supplementary Table S1. The printed cells were incubated in a humidified incubator
(37uC, 5% CO2) for 2 h. Following cell adhesion, cells were grown overnight in BD
FalconTM 6-well tissue culture plates under submerged conditions. On the first day of
incubation, the cell culture media was changed. Co-cultures were printed with the
same printing parameters as described for mono-cultures (Supplementary Table S1).
The sequence of printing was the following: first, a layer of MatrigelTM was printed
followed by a printed layer of EA.hy926 endothelial cells, which were cultured for 2
days before printing the next layer of ECM and the last layer comprising A549
epithelial cells (Fig. 1c).
For manual procedure, MatrigelTM (80 mL) was dispersed with cell scraper over the
surface of cell culture inserts. All disposables, such as pipette tips, cell scrapers were
pre-cooled at -20uC in order to prevent premature polymerization ofMatrigelTM. The
pre-coated membranes were incubated at 37uC for 30 min for ECM gelation. 4.5 3
106 cells/mL EA.hy926 or A549 cells were seeded on MatrigelTM-coated inserts
according to the cell suspension volumes dispensed during the printing process. The
initial calculated cell densities of EA.hy926 andA549 cells on the cell culture transwell
inserts for both conditions i.e., printing andmanual seeding were 1.43 105 and 1.33
105 cells/cm2, respectively.
Cell viability assays. a) Monitoring cell proliferation. The cell confluence was
analysed with an integrated cell culture observation device, BioStation CT (Nikon
Instruments, Zurich, Switzerland), consisting of a tissue culture incubator with built-
in inverted microscope suited to capture 23 to 403 phase contrast and fluorescent
images. Cells were printed/manually seeded on cell culture transwell inserts as
described above and grown in 6-well tissue culture plates for few hours to allow for
cell adhesion. Next, samples were placed in Nikon BioStationCT and a time-lapse
experiment was conducted for 72 h. Bright field and fluorescence (in case of co-
cultures) images were acquired every 2 h from 8 h on and confluence rates were
displayed at 8 h,16 h, 24 h, 36 h, 48 h and 72 h.
Lactate dehydrogenase assay. For the quantification of cell death and cell lysis in
printed and manual samples, a colorimetric assay was employed, which is based on
the measurement of lactate dehydrogenase (LDH) activity released from the cytosol
of damaged cells. For that, cell culture supernatants were collected 3 days after
printing or manual seeding and stored at 4uC until analysis. The LDH cytotoxicity
detection kit (Roche Applied Science, Mannheim, Germany) was used according to
the supplier’s manual. LDHwas quantified photometrically bymeasuring at 490 nm,
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with 630 nm as reference wavelength. Each sample was assessed in triplicate. For
positive controlsmono- and co-cultures were exposed to 0.5%TritonX-100 detergent
in H2O for 24 h at 37uC.
Blue Dextran cell layer integrity assay. The tightness of mono- and co-cultures was
investigated with Blue Dextran dye (Mw 2000 kDa; 17-0360-01 GE Healthcare,
Sigma Aldrich). The principle of the assay is that when the Blue Dextran molecules
are added to the apical side of intact epithelial cell monolayers grown onmicroporous
membrane, the tight junctions between cells will prevent the paracellular transport of
the dye58. Briefly, cells (printed or manually seeded) grown on MillicellH inserts for 3
days were rinsed with PBS, 1 mL of complete phenol red free cell culturemediumwas
added in plate wells, in the lower compartment of the inserts and 250 mL to the upper
compartment on cell layers. Next, 250 mL of 1% Blue Dextran (dissolved in PBS) was
added to the apical surface and incubated for 2 h at 37uC in the incubator. The
contents of lower and upper compartments were collected separately and the passage
of Blue Dextran in basolateral samples was finally quantified using multimode plate
reader (BioRad Benchmark Plus, R&D Systems) by measuring the absorbance at
600 nm.
Immunocytochemistry. The insert membranes with cells were washed in phosphate
buffered saline (PBS) and fixed for 15 min at room temperature in 4%
paraformaldehyde (PFA) in PBS. The fixed cells were incubated with primary and
secondary antibodies for 2 h and 60 min, respectively, at room temperature in dark.
Antibodies were diluted in PBS (containing 0.3% Triton X-100 and 1% BSA) as
follows: mouse anti-human PECAM-1 (10G9) 1550 (sc-13537; Santa Cruz
Biotechnology, Heidelberg, Germany), mouse anti-human VE-cadherin (F-8) 1550
(sc-9989; Santa Cruz Biotechnology, Heidelberg, Germany), goat anti-mouse IgG
H&L 15200 (Alexa FluorH 647 ab150119; Lucernachem, Luzern, Switzerland). The
cytoskeleton i.e., F-actin-filaments of the cells were stained with rhodamine
phalloidin 1550 (R-415; Molecular Probes, Life Technologies Europe B.V., Zug,
Switzerland) and cell nuclei were stained with DAPI 15100 (1 mg/mL; Sigma
Aldrich). The samples were finally mounted in Dako Glycergel Mounting Medium
(DAKO Schweiz AG, Baar, Switzerland).
Laser scanningmicroscopy and image restoration.An inverted Zeiss laser scanning
microscope (LSM) 710 (Axio Observer.Z1, Zeiss, Switzerland) equipped with Ar
488 nm, HeNe 543 nm and HeNe 633 nm lasers was used for visualization of
samples and image acquisition. LSM images were further analysed using Imaris, a
three-dimensional multi-channel image processing software (Bitplane AG, Zurich,
Switzerland).
Histological staining and brightfield microscopy. To visualize and compare the
presence and thickness of ECM layers in samples prepared with two approaches
(printed vs. manual) they were stained with Masson Goldner trichrome stain suited
for distinguishing cells from surrounding connective tissue. Briefly, samples were
fixed in 4% PFA, dehydrated in 100% ethanol and xylol and subsequently embedded
in paraffin. Serial 10-mm thick paraffin sections were cut with a microtome and
collected on Super Frost Plus slides. The staining was performed on rehydrated
sections following standard procedures and resulted red cytoplasm, green collagen
fibers and dark brown cell nuclei. Bright field images (203) were acquired with a
Hamamatsu digital slide scanner (NanoZoomer 2.0-HT, Hamamatsu Photonics) and
further analysed with NDP.view2 viewer software (Hamamatsu Photonics).
Statistical analysis. Results were averages from three independent experiments; each
sample was assessed in triplicates. The results are presented asmean6 SD.A one-way
analysis of variance (ANOVA) was performed by using GraphPad Prism software
(version 6; GraphPad Software Inc., La Jolla, California, USA) and considered
significance at p , 0.05.
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